Developing preclinical models of neuroblastoma: driving therapeutic testing

Area of Science:

• Oncology
• Pediatric Cancer Research
• Preclinical Drug Development

Background:

• Neuroblastoma (NB) is a common pediatric cancer with a high-risk survival rate of 40-50%.
• The heterogeneous nature of NB presents significant challenges for developing effective therapeutic strategies.
• Advances in immuno-oncology have not yet overcome these treatment hurdles.

Purpose of the Study:

• To review current in vitro and in vivo preclinical testing models for neuroblastoma.
• To discuss the potential applications of these models in therapeutic development.
• To highlight the importance of models that accurately reflect tumor heterogeneity.

Main Methods:

• Discussion of traditional in vitro models and their limitations.
• Analysis of in vivo mouse models (genetic, syngeneic, xenograft) for replicating tumor-stroma interactions.
• Exploration of emerging tissue-engineered models as a bridge between in vitro and in vivo systems.

Main Results:

• In vitro models offer high throughput but have limitations in mimicking the tumor microenvironment.
• In vivo models are considered the gold standard for preclinical testing due to their ability to replicate complex interactions.
• Tissue-engineered models show promise in bridging the gap between simpler and more complex preclinical systems.

Conclusions:

• Accurate preclinical models are crucial for developing targeted therapies that address tumor heterogeneity in neuroblastoma.
• The evolution of therapeutics necessitates improved models for effective preclinical testing.
• Further development and validation of advanced preclinical models are essential for advancing neuroblastoma treatment.